page18
Changes for this edition
Significant changes
The BNF is revised twice yearly and numerous changes
are made between issues.
All
copies of
BNF No.
60
(September 2010)
should therefore be withdrawn and
replaced by BNF No.
61 (March 2011).
Significant
changes have been made in the following sections for
BNF No.
61:
Bowel cleansing preparations,
section 1.6.5
Atrial fibrillation and atrial flutter,
section 2.3.1
Dronedarone [NICE guidance],
section 2.3.2
Hypertension in pregnancy,
section 2.5
Hypertensive crises [title ‘Accelerated or
very severe
hypertension’
amended to ‘Hypertensive crises’
and
advice updated],
section 2.5
Sitaxentan (
Thelin
c
) [to be withdrawn from the market
due to hepatotoxicity],
section 2.5.1
Heart failure,
section 2.5.5
Management
of
stroke [new prescribing notes on the
management
of
transient
ischaemic attack,
ischaemic
stroke,
and intracerebral haemorrhage],
section 2.9
Clopidogrel
and modified-release dipyridamole [NICE
guidance],
section 2.9
Familial hypercholesterolaemia, section 2.12
Formoterol
dose
in children [MHRA/CHM advice],
section 3.1.1.1
Fentanyl
[counselling for the use of
patches],
section
4.7.2
Epilepsy in pregnancy,
section 4.8.1
Alcohol dependence,
section 4.10.1
Nicotine dependence,
section 4.10.2
Opioid dependence,
section 4.10.3
Missed maintenance doses in opioid dependence,
sec-
tion 4.10.3
Summary of antibacterial therapy [advice reformatted],
section 5.1, Table 1
Meningitis,
section 5.1,
Table 1
Urinary-tract infections [culture and sensitivity testing],
section 5.1.13
Treatment of fungal infections: aspergillosis, section 5.2
Treatment of fungal infections: invasive or disseminated
candidiasis,
section 5.2
Indinavir [application of
‘less suitable for
prescribing’
symbol],
section 5.3.1
Saquinavir [changes to cautions and contra-indications],
section 5.3.1
Peginterferon alfa,
interferon alfa,
and ribavirin for
chronic hepatitis C [NICE guidance],
section 5.3.3
Palivizumab [updated advice],
section 5.3.5
Prophylaxis against malaria [recommendations for Mor-
occo and Turkmenistan removed], section 5.4.1
Rosiglitazone [marketing authorisation suspended], sec-
tion 6.1.2.3
Liraglutide for the treatment of type 2 diabetes mellitus
[NICE guidance],
section 6.1.2.3
Diabetic ketoacidosis, section 6.1.3
Treatment of hypoglycaemia, section 6.1.4
Denosumab for the prevention of osteoporotic fractures
in postmenopausal
women [NICE guidance],
section
6.6.2
Recurrent vulvovaginal
candidiasis [updated treatment
regimens],
section 7.2.2
Combined hormonal contraceptive interactions, section
7.3.1
Combined oral contraceptives [preparations tabulated],
section 7.3.1
Imatinib for the adjuvant treatment of gastro-intestinal
stromal tumours [NICE guidance],
section 8.1.5
Imatinib for the treatment of unresectable and/or meta-
static
gastro-intestinal
stromal
tumours
[NICE gui-
dance],
section 8.1.5
Trastuzumab for the treatment of HER2-positive meta-
static gastric cancer [NICE guidance],
section 8.1.5
Bevacizumab and sunitinib:
risk of osteonecrosis of the
jaw [MHRA/CHM advice],
section 8.1.5
Caution when dispensing mycophenolate mofetil
[new
brand available],
section 8.2.1
Rapamune
c
tablets [0.5 mg tablet not bioequivalent to
other strengths], section 8.2.2
Eltrombopag for the treatment of chronic immune (idio-
pathic)
thrombocytopenic
purpura [NICE guidance],
section 9.1.4
G6PD deficiency [rasburicase and risk of
haemolysis],
section 9.1.5
Calcium gluconate injection [MHRA advice],
section
9.5.1
Drugs unsafe for use in acute porphyrias,
section 9.8.2
Etanercept,
infliximab,
and adalimumab for
psoriatic
arthritis [NICE guidance], section 10.1.3
Adalimumab, etanercept, infliximab, rituximab, and aba-
tacept for rheumatoid arthritis after the failure of a TNF
inhibitor [NICE guidance],
section 10.1.3
Tocilizumab for rheumatoid arthritis [NICE guidance],
section 10.1.3
Distigmine [removal
of
monograph for
use in myas-
thenia gravis],
section 10.2.1
Aqueous cream [skin reactions when used as a leave-on
emollient],
section 13.2.1
Immunisation schedule,
section 14.1
Haemophilus type B conjugate vaccine in complement
deficiency,
section 14.4
Influenza vaccines, section 14.4
Meningococcal vaccines in complement deficiency, sec-
tion 14.4
Adult
advanced life support
algorithm [Resuscitation
Council
(UK)
updated algorithm 2010],
inside back
cover
xvi
BNF 61